Cellectis (NASDAQ:CLLS) Share Price Passes Below Fifty Day Moving Average – Time to Sell?

Cellectis S.A. (NASDAQ:CLLS)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.70 and traded as low as $3.59. Cellectis shares last traded at $3.63, with a volume of 29,099 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. Citizens Jmp restated a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Jefferies Financial Group assumed coverage on Cellectis in a research note on Tuesday, February 17th. They set a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Cellectis presently has an average rating of “Moderate Buy” and an average target price of $6.75.

Cellectis Stock Down 1.1%

The company has a market capitalization of $364.23 million, a price-to-earnings ratio of -5.42 and a beta of 2.94. The firm has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $4.03. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently bought and sold shares of the company. Lido Advisors LLC acquired a new position in Cellectis in the first quarter worth about $32,000. Marshall Wace LLP grew its stake in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Cellectis in the fourth quarter worth about $15,385,000. Global Retirement Partners LLC acquired a new position in Cellectis in the fourth quarter worth about $34,000. Finally, Millennium Management LLC grew its stake in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.